Abstract: Migrants, defined as individuals who move from their country of origin to another, account for 40% of newly-diagnosed cases of human immunodeficiency virus (HIV) in the European Union/European Economic Area (EU/EEA). Populations at high risk for HIV include migrants, from countries or living in neighbourhoods where HIV is prevalent, and those participating in high risk behaviour. These migrants are at risk of low CD4 counts at diagnosis, increased morbidity, mortality, and onward transmission. The aim of this systematic review is to evaluate the effectiveness and cost-effectiveness of HIV testing strategies in migrant populations and to estimate their effect on testing uptake, mortality, and resource requirements. Following a systematic overview, we included four systematic reviews on the effectiveness of strategies in non-migrant populations and inferred their effect on migrant populations, as well as eight individual studies on cost-effectiveness/resource requirements. We assessed the certainty of our results using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The systematic reviews reported that HIV tests are highly accurate (rapid test >90% sensitivity, Western blot and ELISA >99% sensitivity). A meta-analysis showed that rapid testing approaches improve the access and uptake of testing (risk ratio = 2.95, 95% CI: 1.69 to 5.16), and were associated with a lower incidence of HIV in the 
community-based, and other rapid testing techniques [15] . Migrants from Sub-Saharan Africa and Latin America are more likely to be diagnosed late (defined as having a CD4 count of less than 350 CD4+ cells/mm 3 ) in comparison to non-migrant Europeans [2, 8] . Late diagnosis increases the disease transmission rate, and increases the risk of morbidity and mortality [16] . The main reasons for late diagnosis among migrants are believed to include impaired access to testing as a result of HIV-related stigma, fear, guilt, economic difficulties, and difficulties accessing health care in Europe [8] . This review focuses on the newly arrived migrants to the EU/EEA, who migrated within the past five years, with consideration given to country and origin, circumstances of migration, gender, and age, where relevant. This group of migrants is often less well integrated into health systems because of a lack of reliable access to health services, poor information about healthcare, lack of supportive language provision, and inattention to the gender dimensions of healthcare [17] . While marginalized migrants were the specific focus, we recognize that other migrant populations may also benefit from this review. We conducted a systematic review on the effectiveness, as well as a second systematic review on the cost-effectiveness, of screening for HIV among migrants in the EU/EEA region, with the aim of informing the development of ECDC migrant screening guidance.
Methods
Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach; the Campbell and Cochrane Collaboration Equity Methods Group; and a review team including clinicians, public health experts, and researchers from across the EU/EEA, to conduct the evidence syntheses. A detailed description of the methods can be found in the registered systematic review protocol [18] .
The review group followed the PRISMA reporting guidelines [19] for the reporting of this systematic review (PROSPERO [CRD42016045798]). In summary, the review team developed key research questions (PICO: population, intervention, comparison, and outcome) and a logic model showing an evidence chain to identify key concepts, to consider potential role of indirect evidence related to populations and interventions, and to support the formulation of search strategies (see Appendices A and B) [18] . The review teams aimed to answer the following overarching questions.
• Should newly arrived migrants be screened for HIV? Who should be targeted and how? • What implementation considerations should be considered when screening for HIV in newly arrived migrants to the EU/EEA?
'Migrants', a focus for the eligible evidence, included asylum seekers, refugees, undocumented migrants, and other foreign-born residents, with a focus on newly arrived migrants from HIV intermediate (>0.1%) and high (>1%) prevalence countries to EU/EEA in the last five years. Our analysis did not consider specific subgroups of migrants, but rather, it focused on those that were at high risk of exposure and facing poor access to testing and treatment. This review included various rapid testing approaches and provider-initiated testing approaches. Evidence was evaluated using a hierarchical approach, whereby systematic reviews/meta-analyses, and evidence based guidelines were given the most weight, followed by individual randomized controlled trials (RCTs), quasi-experimental studies, and observational studies [20, 21] . The availability of existing high quality systematic reviews on these topics led us to follow a review of reviews methodology, thereby excluding all of the articles that were not systematic reviews. The team sought to build on existing high quality evidence and to identify gaps that may exist in the evidence-base.
Relevant search terms and strategies were used to search published literature in Ovid MEDLINE, Database of Abstracts of Reviews of Effects (DARE), Cochrane Database of Systematic Reviews (CDSR), and EMBASE from 2010 to December 2016, and NHS EED, CEA Registry (Tufts University), and Google Scholar from 1995 to 2016 (See Appendix B), and grey literature through Google, as well as the U.S. Centres for Disease Control and Prevention (CDC), ECDC, UNAIDS, and WHO websites. The general search terms used included "HIV", "AIDS", "screening", "early diagnosis", and "disease surveillance" (see Appendix B for complete search strategy). No language restrictions were applied to the searches. Migrants and refugees were key populations of interest, but we also considered studies that included marginalised populations with a high prevalence of HIV.
Two independent team members (Tamara Lotfi and Lama Kilzar) manually reviewed the titles, abstracts, and full text of identified citations; selected evidence for inclusion; and compiled evidence reviews and PRISMA flow sheets. Disagreements were resolved by consensus or the involvement of a third reviewer. We assessed the methodological quality of the potentially included studies with AMSTAR [22] or Newcastle Ottawa Newcastle Scales [23] . For evidence of cost-effectiveness, we extracted data from relevant study designs (e.g., micro-costing studies, within-trial cost-utility analyses, and Markov models) for three specific questions, namely: the size of the resource requirements, the certainty of evidence around resource requirements, and whether the cost-effectiveness results favoured the intervention or comparator [24] . Finally, we assessed the certainty of the economic evidence in each study using the relevant items from the 1997 Drummond checklist [25] . The team created tables showing the characteristics of the included studies (see Tables 1 and 2 ), then rated the certainty of the effects for pre-selected outcome measures, and finally, conducted meta-analyses and created GRADE evidence profiles.
The final analysis report was on the GRADE synthesis. The certainty of the evidence rating reflects the level of confidence in an estimate of the desirable and undesirable effects. The implementation considerations were informed by exisiting literature.
Results
We retrieved 4241 articles on the effectiveness of HIV testing options. After the removal of duplicates, 3158 studies were screened by title and abstract for eligibility, based on our PICO criteria (see Table A1 in Appendix C). Of these, 34 studies were screened for full-text, and 30 studies were excluded at the full-text stage. The reasons for exclusion were that the intervention was not HIV testing (n = 25), conference abstract (n = 1), and not a systematic review (n = 4). Four systematic reviews were included in the end [26] [27] [28] [29] (see Figure 1a) . Additionally, 7346 economic studies were identified. After the removal of duplicates, we screened 6241 titles and abstracts for eligibility, and filtered the remaining records with "cost" and "review" in the title or abstract. Of the remaining 13 articles, 12 articles were selected for a full-text review. Eight studies were included [30] [31] [32] [33] [34] [35] [36] [37] (see Figure 1b) . Four studies were excluded, as a result of relevance to our PICO criteria.
Our systematic review evaluated voluntary HIV testing approaches among migrants from HIV intermediate (>0.1%) and high (>1%) prevalence countries arriving to the EU/EEA. This included various rapid testing approaches and provider-initiated testing approaches. Only one randomised-controlled trial (RCT), from the United States [38] , explicitly identified migrants within their study population. This study was included in Pottie (2014) . The GRADE methodology to assess the certainty of evidence considers differences in the study populations and interventions (indirectness) as a potential reason to downgrade the level of certainty (See Table 3 ), allowing us to interpret the findings consistently for the migrant populations [39] . None of the systematic reviews contained any RCTs or observational studies comparing clinical outcomes between indiviuals screened or not screened for HIV infection. No RCT or observational study evaluated the value of repeat HIV testing compared with one-time testing, or of different strategies for repeat testing. No studies compared the effects of different pre-or post-test HIV counselling methods on testing uptake or rates of follow up, and linkage to care. testing (n = 25), conference abstract (n = 1), and not a systematic review (n = 4). Four systematic reviews were included in the end [26] [27] [28] [29] (see Figure 1a) . Additionally, 7346 economic studies were identified. After the removal of duplicates, we screened 6241 titles and abstracts for eligibility, and filtered the remaining records with "cost" and "review" in the title or abstract. Of the remaining 13 articles, 12 articles were selected for a full-text review. Eight studies were included [30] [31] [32] [33] [34] [35] [36] [37] (see Figure 1b) . Four studies were excluded, as a result of relevance to our PICO criteria. Our systematic review evaluated voluntary HIV testing approaches among migrants from HIV intermediate (>0.1%) and high (>1%) prevalence countries arriving to the EU/EEA. This included various rapid testing approaches and provider-initiated testing approaches. Only one randomised-controlled trial (RCT), from the United States [38] , explicitly identified migrants within their study population. This study was included in Pottie (2014) . The GRADE methodology to assess the certainty of evidence considers differences in the study populations and interventions The majority of studies were conducted before WHO PITC guidelines were developed, indicating that provider-initiated testing was occurring in many locations prior to global guidance. All studies included in this review that reported rates of HIV testing uptake showed increases associated with a PITC approach. Comparing behavior in the three months preceding PITC to behavior in the three months after PITC, the percentage of participants who reported engaging in risky sex decreased and knowing their partner's HIV status increased for both HIV-positive and HIV-negative participants. Allowance made for uncertainty. One-way sensitivity analysis performed in a cost analysis model. Range of sensitivity analysis is +/− 50% of the base value, or as wide as possible in the absence of hard data. Rank order of two-step rapid relative to standard C/T sensitive to the return rate for standard C/T, but one-step rapid consistently least expensive.
Cost analysis study using a decision analysis model, costs estimated from both societal and provider perspective, in 2000 U.S. dollars
United States of America
Standard ELISA C/T vs. both one-step (multiple rapid assays) and two-step rapid C/T (i.e., with a confirmatory Western blot test)
From both a provider and societal perspective, costs vary based on sero-status. However, one-step rapid testing is consistently the lowest cost option, and two-step rapid testing tends to be the highest cost. There appear to be cost savings of using a one-step rapid C/T protocol vs. standard ELISA testing or two-step rapid C/T. [28] . However, the review found that targeted screening programmes, which test patients with identified risk factors, may still have missed a proportion of cases [28] . The universal opt-out rapid testing strategy was associated with a higher likelihood of testing compared with physician-directed, targeted rapid testing (25% vs. 0.8%; relative risk [RR] = 30 [95% CI: 26 to 34]), but not necessarily in marginalised populations [28] . Universal testing was also associated with a higher median CD4 count and lower likelihood of CD4 count <200 cells/mm 3 at the time of diagnosis, compared with targeted HIV testing, but these differences were not statistically significant [28] .
New HIV diagnoses detected through universal testing in the United States had follow-up rates that were reported to be between 75-100% [28] . One study directly compared universal and targeted testing strategies [40] . Both the universal and targeted strategies resulted in very high rates of follow up (defined as attending at least one HIV clinic visit) between 97% and 100% [40] . The sample sizes of the included studies were small (range of 17-74 newly diagnosed HIV infections). The U.S. AHRQ review also reports that the treatment was very effective at improving clinical outcomes in adolescent and adult patients with advanced immunodeficiency [28] . The evidence indicates, from primary studies of included systematic reviews, that treatment reduced the risk of AIDS-defining events and mortality in persons with less advanced immunodeficiency and reduced sexual transmission in discordant couples [41] .
In the EU/EEA, migrants from HIV-endemic countries were at a high risk of HIV infection [42] . The groups identified as having a high HIV prevalence were people originating from Sub-Saharan African, Latin America, Southeast Asia, and Eastern Europe [2, 42] . These migrants had a higher frequency of delayed HIV diagnosis and are more vulnerable to the negative effects of the disclosure of their HIV status [42] . For migrants from countries where HIV prevalence is low, their socio-economic vulnerability put them at risk of acquiring HIV post-migration [42] . Migrants tended to report high-risk behaviour for HIV, such as multiple sexual partners, low and inconsistent condom use, high alcohol consumption, and drug use [42] . Men who have sex with men (MSM); sex workers, both male and female; and migrant women are considered particularly vulnerable populations within this group [42] .
One systematic review and meta-analysis focused on the effectiveness of rapid tests for high-risk populations for HIV exposure. One of the RCTs included migrants-specific [38] , and the others involved high-risk marginalised populations. The results of the included systematic review found that rapid voluntary counselling and testing was associated with a large increase in HIV-testing uptake and receipt of results in comparison to conventional testing (RR = 2.95, 95% CI: 1.69-5.16), but these studies did not report on uptake of HIV treatment [26] . The GRADE quality of the included studies was assessed to be low, because of the risk of bias and imprecision. All of the harms of rapid testing were not considered for the scope of the present review.
Repeat testing was found to be more likely among the individuals where rapid testing was performed (RR = 2.28, 95% CI 0.35 to 15.07) [26] . Retesting was also more likely for the individuals who were reminded to re-test by short message service (SMS) text messaging (pooled Odds ratio (OR) 2.19 [95% CI 1.46 to 3.29]) [29] . Receiving phone calls, verbal advice, and/or counselling also resulted in higher rates of retesting than phone calls alone (OR 2.50 [95% CI 1.3 to 4.8]) [29] . In the communities where rapid HIV testing was implemented, the HIV incidence decreased by 11% in comparison to the control arm communities [26] . The evidence for the uptake of HIV testing, receipt of results, and repeat testing were considered of moderate quality, because of randomisation and allocation concerns. In the review that addressed provider initiated treatment and counselling (PITC), nineteen studies were included, all from Sub-Saharan Africa (n = 15) or Asia (n = 4) [27] . The majority (13/19) of studies were conducted before the WHO PITC guidelines were developed in 2007, indicating that provider-initiated testing was occurring in many locations prior to the publication of global guidance. All of the studies that reported rates of HIV testing uptake showed increases in the HIV testing uptake associated with a PITC approach. The PITC's impact on other outcomes does not appear to be worse than voluntary counselling and testing (VCT).
Cost-Effectiveness
Three studies reported the cost-effectiveness of HIV testing strategies. Ekwueme [34] compared the costs of three HIV counselling and testing technologies, standard, one-step, and two-step rapid protocols. The standard protocol (i.e., ELISA) plus counselling and treatment, or one-step testing, was found to be less expensive than the third technology for all of the plausible ranges of HIV seroprevalence [34] . In low prevalence settings, a single rapid assay was cost-effective, as no follow-ups were required nor the use of the expensive Western blot confirmatory assay [34] . The second study, by Doyle [35] , compared testing with an enzyme linked immunosorbent assay to rapid testing with Oraquick. In a low prevalence Mexican setting of 0.05%, rapid testing with Oraquick was the cost-effective strategy, at $217,718 per HIV case prevented. Assuming a 70-year lifespan, this equated to $3111 per life-year gained [35] . The third study, by Paltiel [36] , compared testing with ELISA to the current practice (background testing OR presentation with opportunistic infections), in high (3%) prevalence, medium (1%) prevalence, and low (0.1%) prevalence settings. The addition of a one-off ELISA test was cost-effective compared to the current practice, for prevalence rates of 3% and 1%, but not cost-effective at a prevalence rate of 0.05% (incremental cost-effectiveness ratio: $113,000/QALY (Quality-adjusted Life Year) gained) [36] .
The evidence supporting multiple rapid-tests, rather than a single rapid test followed by later confirmatory test if positive, were mixed. One study supported the use of a single rapid test [32] , while another suggested possible cost savings with multiple rapid assays [34] . In this study, however, the cost advantage of multiple rapid assays was sensitive to HIV seroprevalence. In low prevalence settings (<0.1%), a single rapid assay was likely to be cost effective. The rapid tests evaluated in early economic studies were generally reported to have a lower sensitivity than ELISA tests [30, 33] . Rapid testing is expanding to self-administered oral swabs. Of the limited economic evidence regarding rapid test false positives, one study [35] indicated a predictive value of 100% of the Oraquick rapid test, even in a low prevalence population (as low as 1 in 1000). Another study [36] assigned a loss of 14 quality-adjusted days to patients who received a false positive result from rapid testing. The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI-confidence interval; RR-risk ratio; GRADE working group grades of evidence: high quality: we are very confident that the true effect lies close to that of the estimate of the effect; moderate quality: we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; very low quality: we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the estimate of effect. Interpreting relative values (e.g., uptake of testing) from the summary of findings 
Discussion
Our systematic review provides insight into HIV testing strategies to improve access and uptake in migrant populations in the EU/EEA, following the effectiveness and cost-effectiveness considerations.
In relation to our first research question, there were several HIV testing approaches. The literature showed three leading strategies, rapid testing, conventional testing, and universal testing approaches. Voluntary rapid tests improve HIV testing and uptake and have the potential to improve linkage to counselling and treatment for migrant populations. The universal opt-out testing approach has good intentions but lacks community outreach. Given the effectiveness of HIV treatment, measures and strategies are needed in order to increase the uptake of testing and to reduce the late diagnosis among migrant populations. However, heterogeneity between the results of the rapid testing approaches (I 2 of 93-99% in Figure 2 ) and limited EU/EEA-specific data suggest inconsistency between studies, thereby limiting our confidence in the transferability of these results across the EU/EEA migrant population contexts. The cost-effectiveness of the intervention, however, suggests that rapid testing is preferable to conventional testing in several contexts, due, in particular, to effective testing and counselling integration.
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Discussion
In relation to our first research question, there were several HIV testing approaches. The literature showed three leading strategies, rapid testing, conventional testing, and universal testing approaches. Voluntary rapid tests improve HIV testing and uptake and have the potential to improve linkage to counselling and treatment for migrant populations. The universal opt-out testing approach has good intentions but lacks community outreach. Given the effectiveness of HIV treatment, measures and strategies are needed in order to increase the uptake of testing and to reduce the late diagnosis among migrant populations. However, heterogeneity between the results of the rapid testing approaches (I 2 of 93-99% in Figure 2 ) and limited EU/EEA-specific data suggest inconsistency between studies, thereby limiting our confidence in the transferability of these results across the EU/EEA migrant population contexts. The cost-effectiveness of the intervention, however, suggests that rapid testing is preferable to conventional testing in several contexts, due, in particular, to effective testing and counselling integration. There is no data on the cost-effectiveness and resource requirements of HIV testing in migrant populations in the EU/EEA. Indirect evidence from the United States and South Africa provide some insight into the resources required. We identified three studies on HIV testing strategies [34] [35] [36] . The economic evidence suggests that rapid testing is likely preferable to conventional testing across a range of contexts, largely due to the ability to more effectively integrate testing and counselling. One study supported the use of a single rapid test [32] , while another suggested possible cost savings with multiple rapid assays [34] . The evidence supporting multiple rapid-tests, rather than a single rapid test followed by a later confirmatory test if positive, is mixed. In low prevalence settings (<0.1%), a single rapid assay may still be cost effective.
Implementation Issues
Identifying and addressing potential barriers to implementing effective and cost-effective HIV testing strategies can further promote access and uptake. Barriers to testing at organisational, provider (cultural competency), patient, and community levels in Europe include a perception of There is no data on the cost-effectiveness and resource requirements of HIV testing in migrant populations in the EU/EEA. Indirect evidence from the United States and South Africa provide some insight into the resources required. We identified three studies on HIV testing strategies [34] [35] [36] . The economic evidence suggests that rapid testing is likely preferable to conventional testing across a range of contexts, largely due to the ability to more effectively integrate testing and counselling. One study supported the use of a single rapid test [32] , while another suggested possible cost savings with multiple rapid assays [34] . The evidence supporting multiple rapid-tests, rather than a single rapid test followed by a later confirmatory test if positive, is mixed. In low prevalence settings (<0.1%), a single rapid assay may still be cost effective.
Identifying and addressing potential barriers to implementing effective and cost-effective HIV testing strategies can further promote access and uptake. Barriers to testing at organisational, provider (cultural competency), patient, and community levels in Europe include a perception of low risk, fear and stigma of the disease and disclosure, discrimination, financial limitations, poor access to care, lack of knowledge of where to obtain testing, and entitlement to medical care due to migration status [3, 43, 44] . The uncertain migration status among migrants to Europe is a barrier to preventive and health services in the EU/EEA [13, 45] . This is especially true of undocumented migrants in the EU/EEA, as their uncertain legal status results in precarious living conditions, and discovery of their HIV status may risk deportation in certain countries [46] . HIV-related stigma is a significant barrier to HIV testing, in addition to challenges with socio-economic status, language barriers, and a poor understanding of European healthcare systems [44] . For many migrants, the barriers outweigh the advantages of testing and treatment [47] , further perpetuating the HIV testing problem.
Migrant [13] populations in Sub-Saharan African [48] were more likely to be tested for HIV if they were of poor health, lost a child or sexual partner to HIV, ART was available, testing was a requirement for marriage preparation, enhanced confidentiality, had strong social networks and support [13, 48] , and had a history of sexually transmitted infections (STIs) [44] . Increasing cultural sensitivity and community engagement in counselling and in community-based approaches with outreach and mobilisation, were highlighted as ways to address and promote access and uptake [15] , reflecting the WHO recommendations for vulnerable populations. More equity oriented research is needed to identify barriers to HIV testing in EU/EEA.
The ECDC antenatal screening for HIV, hepatitis B, syphilis, and rubella susceptibility highlights routine HIV testing for all pregnant women [49] . Certain high income countries such as the United States, Australia, Ireland, and Canada recommend testing refugees from HIV endemic areas within one month of arrival in primary health care settings. Such countries have national recommendations [50] [51] [52] [53] for counselling and testing for refugee and migrant populations. Providing HIV testing during routine consultations was generally appreciated by users as an acceptable way to address user inhibitions in asking for it. Several Latin American migrants in Europe deemed compulsory testing as an acceptable public health measure, while healthcare practitioners reported feeling unprepared to communicate HIV positive results and adjust the flow of care [54] . Most migrants who reported knowing how to access HIV testing, preferred to receive information directly from community practitioners [55] .
In general, HIV testing is cost-effective compared with no testing; the current focus is on which testing strategies are the most cost-effective in a migrant health context. The cost-effectiveness of rapid vs. conventional counselling and testing strengthens the need to increase access and uptake. The sensitivity analyses and analytic frameworks, however, were limited and demonstrate how this field is dynamic, as new rapid oral tests emerge. The cost-effectiveness data of rapid HIV testing in the EU/EEA were not available, but economic evidence about the integration of counselling, testing, and treatment was promising. The precise costs and benefits associated with rapid testing in a variety of EU/EEA member state contexts should be evaluated more closely in high-quality economic studies that directly compare various rapid testing assays to conventional testing with ELISA. Such research would need to provide quantitative evidence of the incremental cost-effectiveness of various strategies, including the uncertainty around these estimates.
Public Health Considerations
It is of particular importance to consider the challenges faced by undocumented migrants in order to increase the access and uptake of HIV testing and treatment programmes in the EU/EEA. We know from large clinical trials that treatment reduces onward transmission by 96% [56] . People living with undiagnosed HIV infection and those diagnosed with HIV but not yet on treatment contribute disproportionately to the number of new HIV infections [57] . Some of the contributing structural/organisational barriers to testing include a lack of migration status, lack of funding, availability of community based services, and discrimination in entitlement to care. More than half of the EU/EEA countries do not provide ART for undocumented migrants [12] , further exacerbating the issue and reducing the likelihood that these individuals will come forward for testing. Certain EU/EEA countries have initiated public health screening programmes for migrants at high risk for HIV infection. The benefits of HIV testing in migrants, at both individual and community levels are recognized by many EU/EEA countries, but developing suitable and comprehensive migrant screening programmes has been a challenge in many countries [13] .
Strengths and Limitations
One of the strengths of this review is that it has used GRADE methodology to assess the certainty of the evidence of the included studies, including recent systematic reviews from the U.S. AHRQ and the WHO guidelines, in combination with recent reviews on rapid testing. This review's strengths lie in identifying barriers to accessing testing, and highlighting the cost-effectiveness of increasing the uptake of HIV testing for migrants. The barriers reported from Europe align with migrant HIV access barriers in other high-income countries.
We identified no migrant-specific HIV screening studies and therefore focused on studies that considered high HIV prevalence populations, many of which considered non EU/EEA migrants. This may limit the transferability of the findings to the EU/EEA context. We also acknowledge the lack of economic evidence for HIV testing approaches in migrants to the EU/EEA. The economic evidence is most relevant to the health system in which the study was undertaken, and therefore non-European studies may not be transferable. In addition, a few studies were more than twenty years old, and the costs may have changed since the resource use data was collected.
Conclusions
The migrants coming from countries with a high HIV prevalence often arrive with HIV related stigma and fear, and the screening and testing approaches need to address this challenge. HIV testing approaches that incorporate voluntary rapid testing programmes and primary care testing for high risk migrant populations may increase the uptake of testing, support timely diagnoses, and should provide more opportunities for linkage to effective treatment among migrant populations. All of the testing strategies may improve early diagnosis; treatment improves the individual's clinical outcomes, reduces AIDS-defining events' morbidity, and decreases mortality rates from HIV-related events, as well as having a clear public health benefit. Voluntary testing with rapid results offers an opportunity to overcome HIV related stigma in communities with high HIV prevalence compared to the conventional techniques for HIV testing alone. 27. remove duplicates from 26 (2080) ************************** (27) #19 #17 in Cochrane Reviews (Reviews and Protocols) (195) *************************** S23 S8 AND S16 AND S22 527 S22 S17 OR S18 OR S19 OR S20 OR S21 220,800 S21 (TI meta analy* or AB meta analy*) 29,599 S20 (MH "Meta Analysis") 24,899 S19 PT review 141,121 S18 PT systematic review 53,358 S17 (MH "Systematic Review") 37,370 S16 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 154,560 S15 contact tracing 1457 S14 (disease* or population) N2 surveillance 18,647 S13 (MH "Population Surveillance+") 5939 S12 (case* or early) N2 (detected or detection* or diagnos* or discover*) 29,738 S11 (MH "Early Diagnosis") 4469 S10 TI ((screened or screening*)) OR AB ((screened or screening*)) 78,064 S9 (MH "Health Screening+") 62,689 S8 S1 OR S2 OR S3 OR S4 OR S5 S6 OR S7 108,656 S7 TX aids N2 (infect* or virus*) 10,961 S6 MW aids 22,515 S5 TX acquired N1 (immunedeficienc* or immune deficienc* or immunodeficienc* or immuno deficienc*) 21,283 S4 (MH "Acquired Immunodeficiency Syndrome") 13,583 S3 TX human N1 (immunedeficienc* or immune deficienc* or immunodeficienc* or immuno deficienc*) 23,570 S2 (hiv or hiv1* or hiv2*) 79,932 S1 (MH "Human Immunodeficiency Virus+") 6511 Appendix C Table A1 . Population, intervention, comparison, and outcome (PICO) inclusion criteria.
Population:
Migrants and refugees to EU/EEA countries (primary population of interest); will consider indirect evidence of marginalized groups in settings of high HIV prevalence
Intervention:
Voluntary testing for HIV
Outcome:
Testing outcomes: testing uptake, HIV incidence Treatment outcomes: Efficacy, withdrawals
